NYSE:MYOV
Delisted
Myovant Sciences Ltd Stock News
$26.98
+0 (+0%)
At Close: Jun 08, 2023
SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12
07:32pm, Wednesday, 13'th Apr 2022 Benzinga
SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences (NYSE:MYOV) and lower its price target from $19.00 to $12.00.
Shares of Myovant Sciences are trading up 8.08% over the
Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
05:47pm, Wednesday, 13'th Apr 2022
Shares of Myovant Sciences plunged this week after a regulatory setback for Myfembree. No reasons were provided by the FDA yet, and the deficiency letter comes as a big surprise.
FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA
06:47pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Though the FDA identified deficiencies in Myovant's (MYOV) Myfembree sNDA for managing endometriosis-associated pain, a final decision on the application is yet to be communicated.
Why Myovant Sciences Stock Is Crashing Today
03:49pm, Tuesday, 12'th Apr 2022 The Motley Fool
The FDA has identified deficiencies with Myovant's regulatory filing for Myfembree.
FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA
03:47pm, Tuesday, 12'th Apr 2022
Though the FDA identified deficiencies in Myovant's (MYOV) Myfembree sNDA for managing endometriosis-associated pain, a final decision on the application is yet to be communicated.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease
Aeglea BioTherapeutics Inc (NAS
Why Myovant Sciences Stock Is Crashing Today
11:49am, Tuesday, 12'th Apr 2022
The FDA has identified deficiencies with Myovant's regulatory filing for Myfembree.
What's Going On With Myovant Sciences Stock Today?
09:32am, Tuesday, 12'th Apr 2022
Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on the Supplemental New Drug Application for MYFEMBR
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
04:00am, Tuesday, 12'th Apr 2022 GlobeNewswire Inc.
BASEL, Switzerland and NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced today an update on the Supplemental New Drug Application (sNDA) for
Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
04:14am, Saturday, 26'th Mar 2022
Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
Myovant secures European recommendation for prostate cancer therapy
03:05pm, Friday, 25'th Feb 2022 Seeking Alpha
Commercial-stage pharma company, Myovant Sciences <> announced Friday that an expert panel of the European Medicines Agency ((EMA)) issued a positive opinion on Orgovyx for…
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
02:00pm, Friday, 25'th Feb 2022 GlobeNewswire Inc.
BASEL, Switzerland, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the Committee for Med
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2021 Results - Earnings Call Transcript
08:18pm, Wednesday, 26'th Jan 2022 Seeking Alpha
Myovant Sciences Ltd. (MYOV) Q3 2021 Earnings Call Transcript
07:00pm, Wednesday, 26'th Jan 2022 The Motley Fool
MYOV earnings call for the period ending December 31, 2021.
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2021 Results - Earnings Call Transcript
03:18pm, Wednesday, 26'th Jan 2022
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2021 Results - Earnings Call Transcript
